Ozempic + Metformin: FDA Label, SUSTAIN-3/4 Evidence & Combination Therapy Review

This YMYL evidence review is part of Weight Loss Rankings’ living editorial database — 300+ research articles and 190+ clinically-reviewed GLP-1 telehealth providers, sourced only from FDA prescribing information on DailyMed and peer-reviewed PubMed literature.

Ozempic plus metformin is one of the most common drug combinations in type 2 diabetes management. Metformin is the long-standing ADA-recommended first-line agent; semaglutide (Ozempic) is the GLP-1 receptor agonist most often added when A1c is not at goal or when cardiovascular or kidney risk supports the GLP-1 mechanism. The combination has been studied directly in two pivotal trials (SUSTAIN-3 and SUSTAIN-4), the FDA label states explicitly that there is no clinically significant pharmacokinetic interaction, and the regimen is endorsed in the ADA Standards of Care in Diabetes-2025. This article walks through what the trials actually showed, how to think about overlapping gastrointestinal side effects, when the hypoglycemia conversation matters, and the renal-function thresholds that determine whether metformin can be continued long-term.

Why this combination is so common (ADA Standards of Care)

The American Diabetes Association’s annually-updated Standards of Care in Diabetes is the canonical US clinical practice guideline for type 2 diabetes management. Section 9 of the 2025 edition — titled “Pharmacologic Approaches to Glycemic Treatment” — describes the sequencing of medications in T2D from initial diagnosis through combination therapy^[6].

For most adults newly diagnosed with type 2 diabetes, metformin remains the recommended first-line pharmacologic agent unless contraindicated. It is inexpensive (generic, often under $10 per month), does not cause hypoglycemia, has decades of safety data, and carries longstanding observational evidence of cardiovascular and possibly mortality benefit from the UKPDS legacy cohort. First-line metformin is then escalated to combination therapy when A1c is not at the individualized target, or when specific cardiorenal indications support a particular second agent.

The 2025 Section 9 algorithm recommends a GLP-1 receptor agonist as part of combination therapy when any of the following are present:

• A1c above the individualized target on metformin alone or on metformin plus another oral agent.
• Atherosclerotic cardiovascular disease or high cardiovascular risk — the SUSTAIN-6 and LEADER trial data anchor this preference.
• Heart failure, where SGLT2 inhibitors are typically preferred but GLP-1 receptor agonists remain an option for additional weight and A1c benefit.
• Chronic kidney disease, where GLP-1 receptor agonists are recommended alongside SGLT2 inhibitors for cardiovascular and renal protection.
• When weight management is a treatment goal — the GLP-1 class produces consistent weight loss in T2D, unlike insulin or sulfonylureas.

Semaglutide (Ozempic) is one of the most-prescribed GLP-1 receptor agonists in the United States precisely because it sits inside this ADA-recommended sequence: add to metformin, achieve additional A1c reduction plus weight loss, with cardiovascular risk-reduction labeling for T2D adults with established cardiovascular disease. The Ozempic plus metformin combination is not a workaround or off-label improvisation; it is the ADA-recommended escalation path for many T2D adults.

No drug-drug interaction — what the FDA label says

The Ozempic FDA prescribing information on DailyMed addresses drug interactions explicitly in Section 7^[8]. For the specific question of whether semaglutide and metformin interact pharmacokinetically — that is, whether one drug changes the absorption, distribution, metabolism, or elimination of the other in a clinically meaningful way — the answer in the dedicated drug-interaction studies submitted to the FDA was no.

Semaglutide’s delayed-gastric-emptying mechanism does have the potential to slow the absorption of co-administered oral medications, and Section 7 of the Ozempic label notes that clinicians should be aware of this general principle. For metformin specifically, the dedicated interaction study did not find a clinically significant change in metformin exposure when co-administered with semaglutide. Conversely, metformin did not affect semaglutide exposure to a clinically meaningful degree.

Practical interpretation for prescribers and patients:

• Standard metformin dosing (typically 500 mg twice daily titrating up to 1,000 mg twice daily, or extended-release 1,500-2,000 mg daily) does not need to be adjusted when Ozempic is added on the basis of a drug-drug interaction.
• Ozempic titration follows the standard 0.25 / 0.5 / 1.0 / 2.0 mg weekly ladder regardless of background metformin^[8].
• No therapeutic-drug-monitoring or extra laboratory follow-up is triggered by the combination — routine T2D monitoring (A1c, eGFR, vitamin B12 on metformin, lipids) is sufficient.
• The absence of a pharmacokinetic interaction does NOT mean the absence of overlapping side-effect profiles, which is a separate clinical issue covered in the GI section below.

For a broader review of GLP-1 drug interactions, see the GLP-1 drug interaction checker with FDA-label-sourced flags for insulin, sulfonylureas, warfarin, oral contraceptives, and levothyroxine.

SUSTAIN-3 and SUSTAIN-4: semaglutide added to metformin

Two of the eight phase 3 SUSTAIN trials directly tested semaglutide on top of metformin background. They are the cleanest evidence base for the Ozempic plus metformin combination.

SUSTAIN-3 (Ahmann 2018)

SUSTAIN-3 was a 56-week, open-label, randomized clinical trial of once-weekly semaglutide 1.0 mg versus once-weekly exenatide extended-release 2.0 mg in 813 adults with T2D on background metformin (with or without a sulfonylurea or thiazolidinedione)^[2]. At week 56:

• Mean HbA1c reduction was -1.5 percentage points on semaglutide versus -0.9 points on exenatide ER (treatment difference -0.62, 95% CI -0.80 to -0.44).
• Mean body-weight reduction was -5.6 kg on semaglutide versus -1.9 kg on exenatide ER (treatment difference -3.78 kg, 95% CI -4.58 to -2.98).
• The proportion of patients achieving HbA1c below 7.0% was 67% on semaglutide versus 40% on exenatide ER.
• GI adverse events (nausea, vomiting, diarrhea) were the most common adverse events on semaglutide, mostly mild-to-moderate and decreasing in incidence over the dose-titration weeks.

SUSTAIN-3 establishes that semaglutide added to background metformin produces clinically meaningful additional A1c and weight benefit compared with another GLP-1 receptor agonist (exenatide ER) added on the same background.

SUSTAIN-4 (Aroda 2017)

SUSTAIN-4 was a 30-week, randomized, open-label trial in 1,089 insulin-naive T2D adults on background metformin (with or without sulfonylureas) randomized to once-weekly semaglutide 0.5 mg, 1.0 mg, or once-daily insulin glargine titrated to target^[3]. At week 30:

• Mean HbA1c reduction was -1.21 percentage points on semaglutide 1.0 mg, -1.05 points on semaglutide 0.5 mg, and -0.83 points on insulin glargine.
• Mean body-weight change was -5.2 kg on semaglutide 1.0 mg and -3.5 kg on semaglutide 0.5 mg, versus +1.2 kg weight gain on insulin glargine — a treatment difference of approximately 6.4 kg in favor of semaglutide.
• Hypoglycemia (any severity) was substantially less common on semaglutide than on insulin glargine, an expected finding given metformin’s and semaglutide’s low hypoglycemia mechanisms compared with insulin titration.

SUSTAIN-4 is the cleanest available test of the question “if I am on metformin and need to intensify, should I add Ozempic or basal insulin?” The answer on the SUSTAIN-4 endpoints was that semaglutide produced greater A1c reduction, substantial weight loss instead of weight gain, and less hypoglycemia. Insulin glargine remains an appropriate choice for many patients (particularly when significant insulin deficiency is present and the goal is maintaining a high insulin reserve), but the SUSTAIN-4 data anchor the ADA recommendation to consider GLP-1 receptor agonists before basal insulin in most insulin-naive T2D adults already on metformin.

Additional A1c reduction + weight loss vs metformin alone

The pivotal SUSTAIN-1 trial tested semaglutide as monotherapy against placebo in T2D adults, producing mean HbA1c reductions of -1.45% (0.5 mg) and -1.55% (1.0 mg) at 30 weeks^[1]. Compared with metformin monotherapy, which typically produces HbA1c reductions in the -1.0 to -1.5 percentage-point range in treatment-naive patients, semaglutide is similarly potent. Combining the two produces additive HbA1c benefit because the mechanisms are complementary: metformin reduces hepatic glucose output (gluconeogenesis); semaglutide enhances glucose-dependent insulin secretion, slows gastric emptying, and reduces appetite.

For weight, the difference between the two is more striking. Metformin is approximately weight-neutral in most clinical contexts (some patients lose a small amount, others gain none). Semaglutide produces meaningful weight reduction in T2D adults — typically -4 to -6 kg in the SUSTAIN trials at the 1.0 mg weekly maintenance dose — without the weight-gain liability of insulin or sulfonylureas. For T2D adults whose treatment goals include both glycemic control and weight management, adding semaglutide to metformin delivers both endpoints in a single escalation.

Put differently: on a metformin background, adding semaglutide produces approximately a half-point of additional HbA1c reduction and approximately 4-7 kg of additional weight loss compared with the active comparators used in the SUSTAIN program. The magnitude is consistent across both SUSTAIN-3 and SUSTAIN-4 and across the broader real-world T2D evidence base. For the head-to-head weight-only comparison of metformin versus GLP-1 receptor agonists outside the T2D context, see the metformin vs GLP-1 weight loss evidence review.

GI side effects can be additive — practical management

The most common practical challenge with the Ozempic plus metformin combination is overlapping gastrointestinal side effects. Both medications cause GI symptoms through different mechanisms and the combination can produce additive nausea, vomiting, diarrhea, abdominal discomfort, and constipation.

Metformin’s GI side effects are mediated through its action on intestinal glucose handling and gut microbiome changes; symptoms include osmotic diarrhea, abdominal discomfort, and flatulence. They are most prominent during initiation and dose escalation, and they typically improve over weeks to months. The extended-release (XR) metformin formulation has a lower GI side-effect rate than immediate-release.

Semaglutide’s GI side effects are mediated through GLP-1 receptor activation in the central nervous system and the gut, producing delayed gastric emptying, nausea, vomiting, and constipation. Symptoms are most prominent during each dose escalation (week 1-2 of each new dose) and improve as the patient acclimates. The standard Ozempic dose-titration cadence is 4 weeks per step (0.25 mg starting dose for 4 weeks; 0.5 mg for 4 weeks; then 1.0 mg or higher as tolerated)^[8].

Practical management strategies when starting Ozempic on a metformin background:

• Use metformin extended-release if not already. Lower GI side-effect burden than immediate-release; generally taken once daily with the largest meal of the day.
• Split immediate-release metformin doses. If immediate-release is in use and switching to XR is not possible, splitting the daily dose (e.g., 500 mg three times daily with meals) is gentler than larger twice-daily doses.
• Slow the Ozempic titration cadence if symptoms are intolerable. Standard cadence is 4 weeks per step but extending to 6-8 weeks per step is a clinically reasonable modification for patients with severe GI symptoms; document this with the prescriber.
• Small-volume hydration, bland-food strategies during the first 1-2 weeks after each Ozempic dose increase. Sip-water-frequently approach, BRAT-style foods (bananas, rice, applesauce, toast), avoid high-fat or large-volume meals that worsen gastroparesis-like symptoms.
• Anti-nausea adjuncts where appropriate. Ondansetron is a commonly-prescribed adjunct during the highest-burden weeks; metoclopramide is generally avoided because of its prokinetic mechanism conflicting with semaglutide’s gastroparesis-like effect.
• Consider holding metformin during severe GI episodes. Particularly if dehydration is a concern, temporarily holding metformin and resuming after symptoms settle is safer than continued dosing with poor oral intake (the metformin sick-day rule).

For a week-by-week breakdown of expected semaglutide side-effect timelines, see the GLP-1 side effect timeline tool.

Hypoglycemia risk profile

Hypoglycemia risk with Ozempic plus metformin alone is low. The mechanistic reason is that neither drug stimulates insulin secretion in a glucose-independent manner:

• Metformin works primarily by reducing hepatic glucose output through AMPK-dependent and AMPK-independent pathways. It does not stimulate pancreatic insulin release, and monotherapy with metformin essentially does not cause hypoglycemia at therapeutic doses.
• Semaglutide produces glucose-dependent insulin secretion — the GLP-1 receptor agonist effect on pancreatic beta cells is amplified by elevated blood glucose and tails off as glucose normalizes. Semaglutide monotherapy carries a low hypoglycemia rate; in SUSTAIN-1 monotherapy vs placebo, severe hypoglycemia events were rare and infrequent in both arms^[1].

The Ozempic plus metformin combination therefore inherits the low hypoglycemia profile of both components. SUSTAIN-3 (vs exenatide ER on metformin background) and SUSTAIN-4 (vs insulin glargine on metformin background) both reported low rates of severe hypoglycemia on semaglutide compared with the active comparators^[2][3].

Hypoglycemia risk rises substantially when Ozempic is added to a regimen that already includes:

• Insulin — both basal (glargine, detemir, degludec) and prandial (lispro, aspart, glulisine). The additive glycemic-lowering effect plus insulin’s glucose-independent action increases hypoglycemia risk meaningfully. The Ozempic label and clinical guidelines recommend reducing the insulin dose (typically by 20% as a starting point, with closer self-monitoring) when semaglutide is added.
• Sulfonylureas — glipizide, glimepiride, glyburide. Sulfonylureas stimulate insulin secretion in a glucose-independent manner and are a leading cause of hypoglycemia in T2D. When Ozempic is added to a regimen containing a sulfonylurea, the sulfonylurea dose is typically reduced by approximately 50% as a starting point, with closer self-monitoring and potential further reduction or discontinuation as A1c improves.
• Meglitinides — repaglinide, nateglinide. Similar mechanism to sulfonylureas; similar dose-reduction considerations apply.

For T2D adults on metformin alone who are starting Ozempic, no proactive dose reduction is typically needed. For T2D adults on metformin plus a sulfonylureas plus Ozempic, the conversation about reducing or discontinuing the sulfonylurea should happen at the start of Ozempic titration, not after a hypoglycemia event.

When to add/remove metformin while on Ozempic

The default clinical posture in 2026 is to continue metformin when Ozempic is added — this is the regimen the SUSTAIN-3 and SUSTAIN-4 trials directly tested, and the regimen the ADA Standards of Care implicitly endorses in the Section 9 algorithm^[6].

Reasons metformin is typically continued when a GLP-1 receptor agonist is added:

• Mechanistic complementarity — hepatic glucose suppression (metformin) plus glucose-dependent insulin secretion plus gastric-emptying-mediated appetite reduction (semaglutide).
• Cost — generic metformin is typically under $10 per month, and discontinuing it removes a cheap and effective component without clear benefit.
• Cardiovascular and possibly mortality benefit signals from the UKPDS legacy cohort and subsequent observational analyses.
• Low hypoglycemia risk and weight neutrality — metformin does not add to hypoglycemia or weight-gain burden of the regimen.

Reasons metformin may need to be removed or reduced while on Ozempic:

• Intolerable GI side effects that worsen when semaglutide is added and do not resolve with the practical management strategies above. The dose may need to be reduced or the drug discontinued if symptoms persist beyond 8-12 weeks of optimized management.
• Renal function decline crossing the FDA contraindication threshold (eGFR below 30 mL/min/1.73 m²) or the not-recommended-to-initiate threshold (30-45). Discussed in the lactic acidosis section below.
• Documented metformin-associated adverse event such as vitamin B12 deficiency (long-term metformin can impair B12 absorption), lactic acidosis (rare), or new severe GI intolerance unrelated to semaglutide initiation.
• Patient preference for a simplified regimen after sustained A1c at target — some patients, particularly those who reach normoglycemia on semaglutide monotherapy with sustained weight loss, ask about discontinuing metformin. This is a clinical judgment call; the typical recommendation is to continue metformin given its safety and cost profile, but it is a discussion worth having with the prescriber.

Adding metformin to a patient already on Ozempic is the inverse scenario and is sometimes appropriate when a T2D adult was initiated on a GLP-1 receptor agonist first (for example, when weight management was the dominant treatment goal) and now needs additional A1c control. Metformin titration in this scenario follows the standard protocol (500 mg with the largest meal, titrating up over weeks) with attention to the additive GI side-effect potential.

Lactic acidosis: when to STOP metformin (renal dysfunction)

Metformin-associated lactic acidosis is rare but is the most-feared metformin-specific adverse event. The FDA-mandated renal contraindications on the metformin label exist specifically to mitigate this risk. The Lalau 2015 Kidney International review is the comprehensive reference for the pharmacology^[7].

Metformin is renally cleared without significant hepatic metabolism. When renal function declines, metformin accumulates, which in turn impairs hepatic mitochondrial function and predisposes to type B lactic acidosis. The risk is meaningfully elevated when eGFR falls below 30 mL/min/1.73 m².

The current FDA metformin prescribing information thresholds are:

• eGFR ≥ 60 mL/min/1.73 m²: No restriction; standard dosing.
• eGFR 45-59: Continue with closer monitoring; assess risks and benefits if eGFR falls further.
• eGFR 30-44: Initiation is not recommended; continuation in patients already on metformin requires reduced dose (typically 1,000 mg daily maximum) and more frequent monitoring.
• eGFR below 30: Contraindicated. Discontinue metformin.

Beyond the chronic eGFR thresholds, metformin should be temporarily held in scenarios that risk acute renal hypoperfusion or contrast-mediated injury:

• Around iodinated contrast imaging in patients with eGFR less than 60 mL/min/1.73 m² (per ACR and FDA guidance) — hold metformin at the time of contrast administration and reassess renal function 48 hours later before resuming.
• During acute illnesses with risk of dehydration or hypoperfusion — severe vomiting, diarrhea, or reduced oral intake (the metformin sick-day rule). Hold metformin until oral intake and hydration are restored.
• Around major surgery or any clinical scenario with anticipated hemodynamic instability.

Ozempic does NOT share these renal contraindications. Semaglutide is metabolized primarily through peptide cleavage and beta-oxidation rather than renal clearance, and the FDA Ozempic label permits use in renal impairment including end-stage renal disease without dose adjustment. In fact, the FLOW trial published in 2024 specifically tested semaglutide in T2D adults with chronic kidney disease and showed kidney-protective benefit (see FLOW trial review for the full data).

The practical implication for the Ozempic plus metformin combination: when renal function declines, the conversation is about metformin dose reduction or discontinuation, not Ozempic. Many T2D adults end up on Ozempic monotherapy (with or without an SGLT2 inhibitor or insulin) after their eGFR falls below the metformin threshold. The flip side is that during stable renal function (eGFR ≥ 45) the combination is unproblematic from a renal perspective and is the regimen the SUSTAIN trials and the ADA Standards of Care endorse.

A note on oral semaglutide (Rybelsus) + metformin

Oral semaglutide (Rybelsus, 14 mg daily tablet) is the same active molecule as Ozempic delivered in a tablet form. For patients who prefer an oral medication, Rybelsus plus metformin is a clinically equivalent regimen.

The PIONEER 6 trial (Husain 2019 NEJM) was the cardiovascular safety trial for oral semaglutide: 3,183 T2D adults at high CV risk on standard background T2D care (predominantly metformin) were randomized to oral semaglutide vs placebo^[5]. The MACE hazard ratio was 0.79 (95% CI 0.57-1.11), establishing non-inferiority for cardiovascular safety on metformin background. This is the tablet-formulation analog of the SUSTAIN-6 evidence for injectable semaglutide.

Practical differences between Ozempic (injectable) and Rybelsus (oral) plus metformin:

• Rybelsus must be taken on an empty stomach with no more than 120 mL of plain water at least 30 minutes before the first food, drink, or other oral medication of the day. This timing interacts logistically with morning metformin dosing — many patients take Rybelsus first thing on waking and metformin with breakfast 30+ minutes later.
• Rybelsus dose ladder is 3 mg / 7 mg / 14 mg daily (titrated monthly). Ozempic is 0.25 / 0.5 / 1.0 / 2.0 mg weekly.
• GI side-effect profiles are similar between formulations; the additive-with-metformin caveats apply equally.
• Cost varies. Rybelsus and Ozempic NovoCare cash-pay prices are typically comparable; insurance coverage may differ.

Frequently asked questions

Related research

• Metformin vs GLP-1 weight loss evidence review — head-to-head weight-loss comparison outside the T2D context, including DPP metformin and STEP-1 semaglutide benchmarks.
• Wegovy vs Ozempic evidence review — the regulatory and dosing differences between the same semaglutide molecule at two FDA-approved doses.
• Full GLP-1 medication list reference — every FDA-approved GLP-1 with brand, manufacturer, indication, dose ladder, and DailyMed SetID links.
• Ozempic for prediabetes evidence review — the off-label landscape for prediabetic adults and where the DPP lifestyle program plus metformin sits as first-line.
• Ozempic without diabetes (off-label evidence) — off-label prescribing landscape for non-diabetic adults and when Wegovy is the on-label equivalent.
• GLP-1 drug interaction checker — FDA-label-sourced interaction flags for the GLP-1 class across common co-medications.
• GLP-1 side effect timeline — week-by-week expected side-effect timeline through Ozempic dose titration.

Important disclaimer. This article is educational information only — not medical advice and not a substitute for consultation with a licensed prescriber. Ozempic and metformin are prescription medications with FDA boxed warnings, contraindications, and individualized dosing considerations. Treatment decisions involving combination therapy, dose changes, or discontinuation must be made with a licensed prescriber who has reviewed the full FDA prescribing information and the individual patient’s history including renal function and concomitant medications. Every regulatory claim in this article is anchored to a primary source (DailyMed Ozempic SPL, peer-reviewed PubMed literature, or the ADA Standards of Care in Diabetes-2025). Weight Loss Rankings does not prescribe, dispense, or endorse any specific medication or pharmacy.